Jazz Pharmaceuticals revenue and financials
$231.39Change from previous close: −1.97%Absolute change: −$4.65
In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.88%
- 2025 vs 2024
- Net margin
- -8.3%
- 2024: 13.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 416 | 408 | 363 | 475 | 88.8 | 430 | 399 | 399 | 331 | 267 | 167 | 307 |
| Depreciation and amortization | 179 | 181 | 179 | 178 | 174 | 165 | 168 | 165 | 163 | 163 | 159 | 163 |
| Capital expenditure | -18.1 | -19.7 | -16.7 | -15.2 | -12.9 | -13.9 | -13.3 | -10.8 | -7.1 | -6.9 | -10.1 | -4.3 |
| Investing cash flow | 355 | 123 | -372 | -328 | -641 | -169 | -193 | 214 | -257 | -272 | 102 | -174 |
| Financing cash flow | -995 | -78.5 | 75.4 | -10.8 | -124 | -814 | -8.3 | 246 | -161 | -56.6 | -100 | -78.5 |
| Share repurchases | -9.5 | -104 | -2.0 | -3.8 | -127 | -67.2 | -4.0 | -152 | -164 | -49.3 | -101 | -76.3 |
| Debt issued | — | — | 0.0 | — | — | — | — | 981 | — | — | — | — |
| Debt repaid | -1,008 | -7.8 | -7.8 | -7.8 | -7.7 | -758 | -7.8 | -583 | -7.8 | -7.8 | -7.8 | -7.8 |
| Effect of exchange rates | -0.6 | -0.4 | 0.0 | 0.2 | 4.6 | 1.7 | -2.3 | 3.1 | -0.8 | -1.7 | 1.8 | -1.0 |
| Net change in cash | -225 | 452 | 65.8 | 136 | -672 | -551 | 195 | 862 | -87.6 | -62.9 | 171 | 53.4 |
| Free cash flow | 398 | 389 | 346 | 459 | 75.9 | 416 | 385 | 388 | 324 | 260 | 157 | 303 |
| Levered free cash flow | 261 | 372 | 294 | 466 | 46.9 | 391 | 468 | 299 | 293 | 333 | 81.8 | 315 |